Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study

ConclusionThe risk of developing hypertension during a treatment with anti-calcitonin gene-related peptide monoclonal antibodies seems low. Anyway, patients with a pre-existing hypertension should be cautiously monitored because they are more likely to develop hypertension.
Source: Neurological Sciences - Category: Neurology Source Type: research